Study Evaluating HKI-272 Administered to Healthy Subjects

Phase 1CompletedNCT00366600

Puma Biotechnology, Inc.56 enrolled

Overview

Safety and tolerability of HKI-272 in healthy subjects; the influence of food intake on the same.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

HKI-272

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy

Northwest Kinetics

Tacoma, Washington, United States

Pharmacokinetics; safety and tolerability; influence of food on the same.

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.